Results 41 to 50 of about 12,907 (206)

DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses

Molecules, 2018
Dipeptidyl peptidase IV (DPP-IV), a new target for the treatment of type 2 diabetes mellitus, degrades incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide. DPP-IV inhibitors shorten the inactivation of GLP-1,
Bo-Ram Kim, Hyo Young Kim, Inhee Choi, Jin-Baek Kim, Chang Hyun Jin, Ah-Reum Han   +5 more
doaj   +1 more source

Characterization of Novel Dipeptidyl Peptidase-IV Inhibitory Peptides from Soft-Shelled Turtle Yolk Hydrolysate Using Orthogonal Bioassay-Guided Fractionations Coupled with In Vitro and In Silico Study

Pharmaceuticals, 2020
Five novel peptides (LPLF, WLQL, LPSW, VPGLAL, and LVGLPL) bearing dipeptidyl peptidase IV (DPP-IV) inhibitory activities were identified from the gastrointestinal enzymatic hydrolysate of soft-shelled turtle yolk (SSTY) proteins.
Nhung Thi Phuong Nong, Yu-Kuo Chen, Wen-Ling Shih, Jue-Liang Hsu   +3 more
doaj   +1 more source

Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts. [PDF]

PLoS ONE, 2012
BACKGROUND: Natural extracts play an important role in traditional medicines for the treatment of diabetes mellitus and are also an essential resource for new drug discovery.
Laura Guasch, Esther Sala, María José Ojeda, Cristina Valls, Cinta Bladé, Miquel Mulero, Mayte Blay, Anna Ardévol, Santiago Garcia-Vallvé, Gerard Pujadas   +9 more
doaj   +1 more source

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection

Pharmaceuticals, 2021
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally.
Praveen P. N. Rao, Amy Trinh Pham, Arash Shakeri, Amna El Shatshat, Yusheng Zhao, Rahul C. Karuturi, Ahmed A. Hefny   +6 more
doaj   +1 more source

Synthetic Approaches to Novel DPP-IV Inhibitors—A Literature Review

Molecules
Dipeptidyl peptidase IV (DPP-IV) is a serine protease whose inhibition has been an object of considerable interest in the context of developing novel treatments for type 2 diabetes mellitus.
Valentin Petrov, Teodora Aleksandrova, Aleksandar Pashev   +2 more
doaj   +1 more source

Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease [PDF]

, 2009
Nonalcoholic fatty liver disease is the most common chronic liver disease in industrialized countries and is considered the hepatic manifestation of metabolic syndrome.

core   +2 more sources

Design and Synthesis of Pyrimidinone and Pyrimidinedione Inhibitors of Dipeptidyl Peptidase IV [PDF]

, 2016
The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma
Michael B. Wallace (2235541), Bumsup Lee (2235517), Robert J. Skene (2235523), Lihong Shi (481066), Zhiyuan Zhang (93194), Kathleen Aertgeerts (1920946), Jun Feng (116162), Marc Navre (2235526), Stephen W. Kaldor (2235532), Stephen L. Gwaltney (2235514), Rongda Xu (2235529), Daniel B. Kassel (2235535), Andy Jennings (2235538), David R. Webb (200468), Jeffrey A. Stafford (2235520)   +14 more
core   +1 more source

Metabolic Syndrome-Preventive Peptides Derived from Milk Proteins and Their Presence in Cheeses: A Review

Applied Sciences, 2020
The metabolic syndrome (MetS) is defined as the occurrence of diet-related diseases such as abdominal obesity, atherogenic dyslipidemia, hyperglycemia (insulin resistance) and hypertension.
Anna Iwaniak, Damir Mogut
doaj   +1 more source

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease ...
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park   +3 more
doaj   +1 more source

Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury

Journal of Cardiovascular Pharmacology and Therapeutics, 2014
Diabetes mellitus is a major risk factor for cardiovascular events and patient death. Many animal and clinical studies are now being conducted exploring the potential of antidiabetic drugs such as glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors to improve cardiovascular outcomes.
Alyssa H, Yoon, Yumei, Ye, Yochai, Birnbaum   +2 more
openaire   +2 more sources